The FDA has started a priority review of Amgen’s tarlatamab for small cell lung cancer (SCLC), the lead drug in the company’s pipeline of bispecific T-cell engager (BiTE) drugs for solid tumours.

Get the latest updates on Amgen's upcoming Q3 earnings results, including insights from analysts on key products and trial ...

Amgen AMGN will report third-quarter 2024 results ... respectively. Imdelltra (tarlatamab), approved for pre-treated advanced ...

Additionally, tarlatamab has shown efficacy in treating patients with brain metastases, further strengthening Amgen's position in the oncology market. Enbrel, one of Amgen's established products ...

Amgen AMGN reported third-quarter 2024 adjusted ... up 88% from the year-ago period. Imdelltra (tarlatamab), approved for pre-treated advanced small cell lung cancer (ES-SCLC) in May 2024 ...

Amgen is posting strong growth across its diversified-medicines portfolio. A new weight-loss drug candidate could be a game-changer for the company. Trading at 17 times earnings, the stock offers ...

Strategic acquisitions and pipeline expansions remain central to future growth plans. Amgen revealed a positive third quarter of 2024, exceeding earnings expectations. Despite some challenges in ...

Additionally, tarlatamab has shown efficacy in treating patients with brain metastases, further strengthening Amgen's position in the oncology market. Enbrel, one of Amgen's established products, ...